0001179110-21-003441.txt : 20210315 0001179110-21-003441.hdr.sgml : 20210315 20210315202803 ACCESSION NUMBER: 0001179110-21-003441 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210315 FILED AS OF DATE: 20210315 DATE AS OF CHANGE: 20210315 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Keson-Brookes Maiken CENTRAL INDEX KEY: 0001693805 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38586 FILM NUMBER: 21743232 MAIL ADDRESS: STREET 1: 35 OAK HILL ROAD CITY: FAYVILLE STATE: MA ZIP: 01745 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Rubius Therapeutics, Inc. CENTRAL INDEX KEY: 0001709401 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 042688109 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 399 BINNEY STREET, SUITE 300 CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-679-9600 MAIL ADDRESS: STREET 1: 399 BINNEY STREET, SUITE 300 CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 edgar.xml FORM 4 - X0306 4 2021-03-15 0 0001709401 Rubius Therapeutics, Inc. RUBY 0001693805 Keson-Brookes Maiken C/O RUBIUS THERAPEUTICS, INC. 399 BINNEY STREET, SUITE 300 CAMBRIDGE MA 02139 0 1 0 0 CLO & Corp. Secretary Common Stock 2021-03-15 4 M 0 25000 7.70 A 25000 D Common Stock 2021-03-15 4 S 0 25000 20.2386 D 0 D Stock Option (Right to Buy) 7.70 2021-03-15 4 M 0 25000 0 D 2029-11-28 Common Stock 25000 225000 D The sale was effected pursuant to a Rule 10b5-1 trading plan, effective January 15, 2020, adopted by the Reporting Person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.69, inclusive. The reporting person undertakes to provide to Rubius Therapeutics, Inc., any security holder of Rubius Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. 25% of this option vested on November 18, 2020, then in 12 equal quarterly installments thereafter. /s/ Joanne M. Protano, Attorney-in-Fact 2021-03-15